Dr. Furman on Exciting Available Agents for Patients With CLL

Richard R. Furman, MD
Published: Friday, Sep 01, 2017



Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the available agents that have shown promise for patients with chronic lymphocytic leukemia (CLL).

The 3 most exciting and important agents in the CLL landscape include ibrutinib (Imbruvica), venetoclax (Venclexta), and obinutuzumab (Gazyva). Although ibrutinib is well tolerated most of time, there are a few patients who have contraindications to it, Furman explains. This mainly includes patients who have bleeding risks or atrial fibrillation. In these cases, venetoclax and obinutuzumab are appropriate alternatives. For patients who also don’t wish for intravenous infusions or are concerned about tumor lysis risks, venetoclax or obinutuzumab can be used.

These 3 therapies are able to induce long-term and deep remissions in patients, Furman adds. While ibrutinib can have good outcomes at 5 years, it takes a long time to induce a deep response, he says. In patients with potential indication of either Richter’s transformation or developing a resistance to ibrutinib, they may have better outcomes and tolerability with venetoclax.


Richard R. Furman, MD, Morton Coleman, M.D. Distinguished Associate Professor of Medicine, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the available agents that have shown promise for patients with chronic lymphocytic leukemia (CLL).

The 3 most exciting and important agents in the CLL landscape include ibrutinib (Imbruvica), venetoclax (Venclexta), and obinutuzumab (Gazyva). Although ibrutinib is well tolerated most of time, there are a few patients who have contraindications to it, Furman explains. This mainly includes patients who have bleeding risks or atrial fibrillation. In these cases, venetoclax and obinutuzumab are appropriate alternatives. For patients who also don’t wish for intravenous infusions or are concerned about tumor lysis risks, venetoclax or obinutuzumab can be used.

These 3 therapies are able to induce long-term and deep remissions in patients, Furman adds. While ibrutinib can have good outcomes at 5 years, it takes a long time to induce a deep response, he says. In patients with potential indication of either Richter’s transformation or developing a resistance to ibrutinib, they may have better outcomes and tolerability with venetoclax.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions & New Answers to Optimize OutcomesAug 16, 20181.5
Community Practice Connections™: Personalized Sequencing in Castration-Resistant Prostate Cancer: Bridging the Latest Evidence to the Bedside in Clinical ManagementAug 25, 20181.5
Publication Bottom Border
Border Publication
x